Chemical pathology V - Plasma lipid and lipoprotein Flashcards

1
Q

6 plasma lipiprotein calsses?

A
HDL
LDL
IDL 
VLDL
Chylomicrons 
Lipoprotein A (LDL variant, pathogenic)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Content and apolipoproteins in HDL?

A

Cholesteyl ester

A-I,A-II, C,E

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Content and apolipoproteins in LDL?

A

CE

B-100

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Content and apolipoproteins in IDL?

A

CE + TG

B-100, C, E

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Content and apolipoproteins in VLDL?

A

TG (liver)

B-100, C, E

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Content and apolipoproteins in Chylomicron?

A

TG (intestine)

B-48, C, E, A-I, A-II, A-IV

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Content and apolipoproteins in Lipoprotein A?

A

CE
B-100
Lipoprotein A

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Morphological classification of serum lipid disorders?

A

Fredrickson classification

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Frederickson phenotype: Type I
Clear or turbid?
Lipoprotein abnormality?
Associated disorders?

A

Creamy top layer

Chylomicron

Lipoprotein lipase deficiency, apolipoprotein C-II deficiency

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Frederickson phenotype: Type IIa
Clear or turbid?
Lipoprotein abnormality?
Associated disorders?

A

Clear

LDL

Familial hypercholesterolemia, polygenic hypercholesterolemia, nephrosis, hypothyroidism, familial combined hyperlipidemia

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Frederickson phenotype: Type IIb
Clear or turbid?
Lipoprotein abnormality?
Associated disorders?

A

Clear

LDL, VLDL

Familial combined hyperlipidemia

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Frederickson phenotype: Type III
Clear or turbid?
Lipoprotein abnormality?
Associated disorders?

A

Turbid

IDL

Dysbetalipoproteinemia

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Frederickson phenotype: Type IV
Clear or turbid?
Lipoprotein abnormality?
Associated disorders?

A

Turbid

VLDL

Familial hypertriglyceridemia, familial combined hyperlipidemia, sporadic hypertriglyceridemia, diabetes

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Frederickson phenotype: Type V
Clear or turbid?
Lipoprotein abnormality?
Associated disorders?

A

Creamy top, turbid bottom

Chylomicrons, VLDL

Diabetes

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Patient:

  • 2/m
  • Healthy
  • Achilles Xanthoma, elbow xanthoma, bilateral
  • No family history, except maternal grandmother stroke from hyperlipidemia
  • High LDL, High total cholesterol, Clear serum

Dx?

A

Clear serum: type IIa or IIb
Most often type IIa

Familial hypercholesterolemia

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Treatment of Familial combined hyperlipidemia

A

Low cholesterol diet

Cholestyramine

17
Q

Which phenotypes in Fredrickson classification of hyperlipidemia have high atherogenicity?

A

Major: IIa, IIb, III

Minor: IV, V

Not atherogenicity: I

18
Q

Which phenotype in Fredrickson classification of hyperlipidemia has normal Plasma TG level?

A

IIa

Only one**

19
Q

3 mutations that cause familial hypercholestrolemia?

A

LDLR gene mutation *** (90%)
APOB (Apolipoprotein B) (10%)
PCSK9 (gain of function) (<5%)

20
Q

3 mutations for autosomal recessive hypercholesterolemia

A

1) LDLR-AP1 reduced expression
2) ABCG5, ABCG8 deficiency > Sitosterolemia
3) CYP7A1 deficiency (decrease bile acid synthesis, high intrahepatic cholesterol)

21
Q

3 main causes of inherited high cholesterol

A

Familial hypercholestrolemia
Familial combined hyperlipidemia
Cerebrotendinous xanthomatosis

22
Q

D/dx cerebrotendinous xanthomatosis with familial hypercholestrolemia causing xanthoma formation

A

Both cause xanthoma

Cerebrotendinous xanthomatosis affects cognitive function, cause paraplegia and dementia, but NOT hypercholestrolemia

23
Q

4 criteria for clinical Dx of Familial hypercholestrolemia

A

1) Positive family history + high LDL
2) Tendon xanthoma + high LDL
3) Very high LDL (>6.2, under 20 years old)
4) DNA test for mutation (85% accurate only, not gold standard)

24
Q

Patient with familial hypercholesterolemia
2 heterozygous mutations in LDLR gene
- One missense (in mother)
- One duplication error (not found in parents)

2 possible cause of duplication error?

A

Germline mosaicism in one parent

De novo mutation

25
Q

What factors affect the phenotype of heterozygous familial hypercholestrolemia?

What factors affect the phenotype of homozygous familial hypercholestrolemia?

A

Heterozygous: phenotype increase by Western lifestyle and diet:
> 90% penetrance of LDLR with markedly high LDL

All homozygous = severely affected

26
Q

Common complication of homozygous familial hypercholesterolemia?

A

Sever coronary heart disease

Onset at mid-20s

27
Q

Treatment of heterozygous and homozygous familial hypercholesterolemia?

A

Heterozygous: Statin + Bile acid-binding resin drugs

Homozygous:

  • LDL apheresis to reduce plasma LDL every 1-4 weeks 1st line, preferred
  • Liver transplant to replace defective hepatic LDLR before coronary heart disease
28
Q

Describe transport of cholesteryl ester in LDL into cells?

Defective transport consequence?

A

CE in LDL is shielded by hydrophilic coating (phospholipid, apoB-100, Unesterified cholesterol)

Receptor - mediated endocytosis of LDL by LDLR takes CE into cells

Defective LDLR on liver cells = accumulation of LDL in plasma

29
Q

MoA of HMG- COA reductase inhibitor and bile acid-binding resin?

A

Bile acid binding resin = stop enterohepatic recycling of bile acid = more excretion of cholesterol into intestines + More LDL intake in hepatocytes to form bile acid (upregulate LDLR)

HMG-CoA reductase inhibitor = stop production of cholesterol in liver = Upregulation of LDLR to uptake plasma LDL to make bile acid for excretion through intestines

30
Q

4 components of blood phytosterol profile test

A

Cholestanol
Campesterol
Stigmasterol
Beta-stiosterol

31
Q

Sitosterolemia.

  • Mutation
  • Effect on metabolism of plant sterols?
  • Disease?
A

ATP-Binding-Cassette: ABC-G5, ABC-G8 mutation

Increase GI absorption and decrease biliary excretion of plant sterols

autosomal recessive hypercholesterolemia

32
Q

Clinical presentation of sitosterolemia?

A
Xanthoma 
Premature atherosclerosis 
Hemolytic anemia 
Large platelets 
Increase plasma concentration of plant sterols: sitosterol, campesterol, stigmasterol
33
Q

Treatment of Sitosterolemia?

Genetic counselling of family?

A

Low plant sterol diet
Ezetimibe: inhibit cholesterol and plant sterol uptake by NPC1L1 transporter
No response to statin

Offsprings are obligate carrier: plasma conc. of plant sterols is normal in carrier

34
Q

3 d/dx of xanthoma formation

A

Familial hypercholestrolemia

Sitosterolemia

Cerebrotendinous xanthomatosis

35
Q
Patient:
50/M 
Chronic achilles tendon xanthoma 
Serum clear
High Campesterol (10x)

Dx?

A

Sitosterolemia

autosomal recessive hypercholesterolemia

ABCG5 and ABCG8 mutations
Increase GI absorption and decrease biliary excretion of plant sterols

36
Q
Patient:
58/M 
Spastic tetraparesis unknown cause 
Wheelchair bound 
Achilles xanthoma 
Clear serum with normal lipid profile, high Cholestanol (3X)

Dx?

A

Cerebrotendinous xanthomatosis

Autosomal recessive lipid storage disease

37
Q

Cerebrotendinous xanthomatosis

  • Inheritance pattern, mutation?
  • Effect of mutation?
  • Clinical manifestation (5)
A

Autosomal recessive lipid storage disease: CYP27A1 mutation
Cholesterol cannot be converted into bile acid&raquo_space; convert to cholestenol and bile alcohol

  • Tendon xanthoma
  • Progressive neurologic dysfunction (dementia, cerebellar, seizures…etc)
  • Chronic diarrhea
  • premature cataract
  • Early onset osteoporosis
38
Q

Treatment for cerebretendinous xanthomatosis?

A

Bile acid replacement therapy (chenodeoxycholic acid, Ursodeoxycholic acid)

> > restart bile acid negative feedback mechanism